共 19 条
[1]
Tuffs A(2001)Bayer faces shake up after Lipobay withdrawn Br Med J 323 828-432
[2]
Archetti F(2007)Genetic programming for computational pharmacokinetics in drug discovery and development Genet Program Evol Mach 8 413-2585
[3]
Lanzeni S(2000)QSAR model for drug human oral bioavailability J Med Chem 43 2575-204
[4]
Messina E(2003)ADMET in silico modeling: towards prediction paradise? Nat Rev Drug Discov 2 192-716
[5]
Vanneschi L(2004)Can the pharmaceutical industry reduce attrition rates? Nat Rev Dug Discov 3 711-414
[6]
Yoshida F(2000)ADME/PK as part of a rational approach to drug discovery Drug Discov Today 9 409-601
[7]
Topliss JG(2012)Bloat free genetic programming: application to human oral bioavailability prediction Int J Data Min Bioinform 6 585-444
[8]
van de Waterbeemd H(1997)Managing the drug discovery/development interface Drug Discov Today 2 436-937
[9]
Gifford E(2006)Prediction of ADMET properties Chem Med Chem 1 920-undefined
[10]
Kola I(undefined)undefined undefined undefined undefined-undefined